117 related articles for article (PubMed ID: 33252239)
21. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.
Zask A; Verheijen JC; Curran K; Kaplan J; Richard DJ; Nowak P; Malwitz DJ; Brooijmans N; Bard J; Svenson K; Lucas J; Toral-Barza L; Zhang WG; Hollander I; Gibbons JJ; Abraham RT; Ayral-Kaloustian S; Mansour TS; Yu K
J Med Chem; 2009 Aug; 52(16):5013-6. PubMed ID: 19645448
[TBL] [Abstract][Full Text] [Related]
22. The T-cell fingerprint of MALT1 paracaspase revealed by selective inhibition.
Bardet M; Unterreiner A; Malinverni C; Lafossas F; Vedrine C; Boesch D; Kolb Y; Kaiser D; Glück A; Schneider MA; Katopodis A; Renatus M; Simic O; Schlapbach A; Quancard J; Régnier CH; Bold G; Pissot-Soldermann C; Carballido JM; Kovarik J; Calzascia T; Bornancin F
Immunol Cell Biol; 2018 Jan; 96(1):81-99. PubMed ID: 29359407
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of MALT1 Decreases Neuroinflammation and Pathogenicity of Virulent Rabies Virus in Mice.
Kip E; Staal J; Tima HG; Verstrepen L; Romano M; Lemeire K; Suin V; Hamouda A; Baens M; Libert C; Kalai M; Van Gucht S; Beyaert R
J Virol; 2018 Nov; 92(22):. PubMed ID: 30158289
[TBL] [Abstract][Full Text] [Related]
24. Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
Arcari JT; Beebe JS; Berliner MA; Bernardo V; Boehm M; Borzillo GV; Clark T; Cohen BD; Connell RD; Frost HN; Gordon DA; Hungerford WM; Kakar SM; Kanter A; Keene NF; Knauth EA; Lagreca SD; Lu Y; Martinez-Alsina L; Marx MA; Morris J; Patel NC; Savage D; Soderstrom CI; Thompson C; Tkalcevic G; Tom NJ; Vajdos FF; Valentine JJ; Vincent PW; Wessel MD; Chen JM
Bioorg Med Chem Lett; 2013 May; 23(10):3059-63. PubMed ID: 23566514
[TBL] [Abstract][Full Text] [Related]
25. Targeting lymphomas through MALT1 inhibition.
Fontan L; Melnick A
Oncotarget; 2012 Dec; 3(12):1493-4. PubMed ID: 23455603
[No Abstract] [Full Text] [Related]
26. From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
Zhang CH; Chen K; Jiao Y; Li LL; Li YP; Zhang RJ; Zheng MW; Zhong L; Huang SZ; Song CL; Lin WT; Yang J; Xiang R; Peng B; Han JH; Lu GW; Wei YQ; Yang SY
J Med Chem; 2016 Nov; 59(21):9788-9805. PubMed ID: 27739679
[TBL] [Abstract][Full Text] [Related]
27. Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.
Bussenius J; Anand NK; Blazey CM; Bowles OJ; Bannen LC; Chan DS; Chen B; Co EW; Costanzo S; DeFina SC; Dubenko L; Engst S; Franzini M; Huang P; Jammalamadaka V; Khoury RG; Kim MH; Klein RR; Laird D; Le DT; Mac MB; Matthews DJ; Markby D; Miller N; Nuss JM; Parks JJ; Tsang TH; Tsuhako AL; Wang Y; Xu W; Rice KD
Bioorg Med Chem Lett; 2012 Mar; 22(6):2283-6. PubMed ID: 22342124
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
29. Quinoline and thiazolopyridine allosteric inhibitors of MALT1.
Scott DA; Hatcher JM; Liu H; Fu M; Du G; Fontán L; Us I; Casalena G; Qiao Q; Wu H; Melnick A; Gray NS
Bioorg Med Chem Lett; 2019 Jul; 29(14):1694-1698. PubMed ID: 31129051
[TBL] [Abstract][Full Text] [Related]
30. MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.
Gehring T; Erdmann T; Rahm M; Graß C; Flatley A; O'Neill TJ; Woods S; Meininger I; Karayel O; Kutzner K; Grau M; Shinohara H; Lammens K; Feederle R; Hauck SM; Lenz G; Krappmann D
Cell Rep; 2019 Oct; 29(4):873-888.e10. PubMed ID: 31644910
[TBL] [Abstract][Full Text] [Related]
31. Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.
Heng H; Wang Z; Li H; Huang Y; Lan Q; Guo X; Zhang L; Zhi Y; Cai J; Qin T; Xiang L; Wang S; Chen Y; Lu T; Lu S
Eur J Med Chem; 2019 Aug; 176():248-267. PubMed ID: 31103903
[TBL] [Abstract][Full Text] [Related]
32. Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.
Jiang F; Wang HJ; Jin YH; Zhang Q; Wang ZH; Jia JM; Liu F; Wang L; Bao QC; Li DD; You QD; Xu XL
J Med Chem; 2016 Dec; 59(23):10498-10519. PubMed ID: 27933959
[TBL] [Abstract][Full Text] [Related]
33. SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Curtin ML; Heyman HR; Clark RF; Sorensen BK; Doherty GA; Hansen TM; Frey RR; Sarris KA; Aguirre AL; Shrestha A; Tu N; Woller K; Pliushchev MA; Sweis RF; Cheng M; Wilsbacher JL; Kovar PJ; Guo J; Cheng D; Longenecker KL; Raich D; Korepanova AV; Soni NB; Algire MA; Richardson PL; Marin VL; Badagnani I; Vasudevan A; Buchanan FG; Maag D; Chiang GG; Tse C; Michaelides MR
Bioorg Med Chem Lett; 2017 Aug; 27(15):3317-3325. PubMed ID: 28610984
[TBL] [Abstract][Full Text] [Related]
34. Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
Heightman TD; Berdini V; Bevan L; Buck IM; Carr MG; Courtin A; Coyle JE; Day JEH; East C; Fazal L; Griffiths-Jones CM; Howard S; Kucia-Tran J; Martins V; Muench S; Munck JM; Norton D; O'Reilly M; Palmer N; Pathuri P; Peakman TM; Reader M; Rees DC; Rich SJ; Shah A; Wallis NG; Walton H; Wilsher NE; Woolford AJ; Cooke M; Cousin D; Onions S; Shannon J; Watts J; Murray CW
J Med Chem; 2021 Aug; 64(16):12286-12303. PubMed ID: 34387469
[TBL] [Abstract][Full Text] [Related]
35. Discovery and SARs of 5-Chloro-
Wang Y; Chen X; Yan Y; Zhu X; Liu M; Liu X
J Med Chem; 2020 Mar; 63(6):3327-3347. PubMed ID: 32129996
[TBL] [Abstract][Full Text] [Related]
36. The Bcl10/Malt1 signaling pathway as a drug target in lymphoma.
Jost P; Peschel C; Ruland J
Curr Drug Targets; 2006 Oct; 7(10):1335-40. PubMed ID: 17073595
[TBL] [Abstract][Full Text] [Related]
37. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
38. Novel pyrazolopyrimidine urea derivatives: Synthesis, antiproliferative activity, VEGFR-2 inhibition, and effects on the cell cycle profile.
Kassab AE; El-Dash Y; Gedawy EM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900319. PubMed ID: 32091161
[TBL] [Abstract][Full Text] [Related]
39. MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression.
Afonina IS; Elton L; Carpentier I; Beyaert R
FEBS J; 2015 Sep; 282(17):3286-97. PubMed ID: 25996250
[TBL] [Abstract][Full Text] [Related]
40. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S
Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
